Aegis is Awarded US Patent for Formulation and Non-invasive Delivery of Peptide Drugs
August 15, 2018 06:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded US Patent No. 10,046,025, providing non-invasive delivery of cyclic peptide drugs....
Aegis Expands its International and US Intravail® Patent Portfolio on Multiple Fronts
August 02, 2018 06:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded European Patent No. EP2381773(B1) and Canadian Patent No. 2,748,268, providing fast...
energias.jpg
Europe Ethoxylated Sorbitan Esters Market to witness a CAGR of 5.9% during 2018-2024
July 17, 2018 07:59 ET | Energias Market Research
NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- The european ethoxylated sorbitan esters market is expected to witness a CAGR of 5.9% during 2018-2024. The growth is attributed to the high demand for...
energias.jpg
Global Ethoxylated Sorbitan Esters Market to witness a CAGR of 5.8% during 2018-2024
July 10, 2018 03:23 ET | Energias Market Research
NEW YORK, July 10, 2018 (GLOBE NEWSWIRE) -- The global Ethoxylated Sorbitan Esters market is expected to witness a CAGR of 5.8%, and is projected to reach USD 840.7 Million by 2024. The growth is...